Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER

Cristiane Bergerot, Shengsheng Yu, Min Yang, Bruno Martins, Mengtian Du, Jose Perez Torrealba, Tasha Hall, Navendu Samant, Robert J Motzer, David Cella

Open source

DOI: 10.1093/oncolo/oyag329
Published: 2026-08-06
Container: The Oncologist
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag329,
  title = {Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER},
  author = {Cristiane Bergerot and Shengsheng Yu and Min Yang and Bruno Martins and Mengtian Du and Jose Perez Torrealba and Tasha Hall and Navendu Samant and Robert J Motzer and David Cella},
  year = {2026},
  journal = {The Oncologist},
  doi = {10.1093/oncolo/oyag329},
  url = {https://doi.org/10.1093/oncolo/oyag329}
}

RIS

TY  - JOUR
TI  - Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER
AU  - Cristiane Bergerot
AU  - Shengsheng Yu
AU  - Min Yang
AU  - Bruno Martins
AU  - Mengtian Du
AU  - Jose Perez Torrealba
AU  - Tasha Hall
AU  - Navendu Samant
AU  - Robert J Motzer
AU  - David Cella
PY  - 2026
JO  - The Oncologist
DO  - 10.1093/oncolo/oyag329
UR  - https://doi.org/10.1093/oncolo/oyag329
ER  -

APA

Bergerot, C., Yu, S., Yang, M., Martins, B., Du, M., Torrealba, J. P., Hall, T., Samant, N., Motzer, R. J., & Cella, D. (2026). Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. The Oncologist. https://doi.org/10.1093/oncolo/oyag329

Source records

crossref · retrieved 2026-09-26T00:06:34.429Z